← Back to Search

Coagulation Factor

BAX855 for Severe Hemophilia A

Phase 3
Waitlist Available
Research Sponsored by Baxalta now part of Shire
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Participant has severe hemophilia A (Factor VIII (FVIII) <1%) as determined by the central laboratory, or a historical FVIII level <1% as determined at any local laboratory, optionally supported by an additional FVIII gene mutation consistent with severe hemophilia A.
Participant is <6 years old at the time of screening.
Must not have
Participant has detectable FVIII inhibitory antibodies (>=0.6 BU using the Nijmegen modification of the Bethesda assay) as confirmed by central laboratory at screening.
Spontaneous disappearance of the inhibitor prior to ITI.
Screening 3 weeks
Treatment Varies
Follow Up throughout part a and part b of the study, approximately 7 years
Awards & highlights


This trial is for young children with severe hemophilia A who have not been treated with BAX855 or other FVIII concentrates. The goal is to check for side effects and learn how well BAX855 controls bleeding.

Who is the study for?
This trial is for children under 6 with severe hemophilia A who haven't been treated with BAX855 or similar treatments. They must have had less than three exposures to certain medications and no history of severe allergic reactions to specific proteins, PEG, or Tween 80. Their liver and kidney functions should be normal, and they shouldn't be on other PEGylated drugs or certain immune-modifying drugs.Check my eligibility
What is being tested?
The study tests BAX855 in young children with hemophilia A for side effects, including the development of antibodies that may reduce its effectiveness. The drug can be used as a regular preventive treatment or given when bleeding occurs. If antibodies develop, additional treatment will be provided within the study.See study design
What are the potential side effects?
Possible side effects include allergic reactions to ingredients in BAX855 like mouse or hamster proteins, PEG, or Tween 80. There's also a risk of developing inhibitors (antibodies) against Factor VIII which could make the treatment less effective.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
I have severe hemophilia A with Factor VIII less than 1%.
I am under 6 years old.
I have had less than 3 treatments with ADVATE, BAX 855, or plasma transfusions.
I have a confirmed positive inhibitor for my condition, with bleeding not controlled by usual treatments.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
My blood test shows I have FVIII inhibitory antibodies.
My inhibitor has disappeared on its own before treatment.
I have severe liver problems, with very high liver enzyme levels or blood clotting issues.
My kidney function is severely impaired.
I have a bleeding disorder that is not hemophilia A.
My weight is expected to be under 5 kg at the start of the study.
I will be taking a strong immune system affecting drug during the study.
I have received more than two doses of ADVATE before joining the study.


Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~throughout part a and part b of the study, approximately 7 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and throughout part a and part b of the study, approximately 7 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of Participants With FVIII Inhibitor Development
Success Rate of Immune Tolerance Induction (ITI)
Secondary outcome measures
Annualized Bleeding Rate (ABR) for Prophylactic and On-demand Treatment
Binding Immunoglobulin G (IgG) and Immunoglobulin M (IgM) Antibodies
Blood Loss Per Participant in Case of Surgery
+16 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: Previously untreated patients (PUPs)Experimental Treatment2 Interventions
Part A (Main Study): Participants age <3 years and not experienced two joint bleeds will receive on- demand treatment of 10-80 international unit per kilogram (IU/kg) of BAX 855 intravenously depending on the severity of the bleeding episode and age <3 years or after a maximum of two joint bleeds will receive prophylaxis treatment with dose of 25-80 IU/kg of BAX855 IV (based on investigator discretion) once weekly for up to 100 EDs. Part A (Surgery): In participants, the administration of BAX 855 will be individualized based on the participants IR and half-life. For major surgery to achieve the target level of 80-100% FVIII in plasma of normal FVIII level and for minor surgery >=30-60% FVIII levels for dental or other invasive surgery. Part B (Immune tolerance induction [ITI]): Participants will receive prophylaxis treatment of 100-200 IU/kg BAX 855 IV daily or 50 IU/kg three time in a week and will be reduced to twice weekly to maintain FVIII trough level of 1% for further 3 months.
First Studied
Drug Approval Stage
How many patients have taken this drug
Rurioctocog alfa pegol
FDA approved

Find a Location

Who is running the clinical trial?

Baxalta now part of ShireLead Sponsor
110 Previous Clinical Trials
8,974 Total Patients Enrolled
52 Trials studying Hemophilia A
3,917 Patients Enrolled for Hemophilia A
Takeda Development Center Americas, Inc.Industry Sponsor
56 Previous Clinical Trials
11,920 Total Patients Enrolled
2 Trials studying Hemophilia A
71 Patients Enrolled for Hemophilia A
Study DirectorStudy DirectorTakeda
1,230 Previous Clinical Trials
500,970 Total Patients Enrolled
65 Trials studying Hemophilia A
4,910 Patients Enrolled for Hemophilia A

Media Library

PEGylated Recombinant Factor VIII (Coagulation Factor) Clinical Trial Eligibility Overview. Trial Name: NCT02615691 — Phase 3
Hemophilia A Research Study Groups: Previously untreated patients (PUPs)
Hemophilia A Clinical Trial 2023: PEGylated Recombinant Factor VIII Highlights & Side Effects. Trial Name: NCT02615691 — Phase 3
PEGylated Recombinant Factor VIII (Coagulation Factor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT02615691 — Phase 3
~3 spots leftby Oct 2024